JP Morgan Chase
CGTX icon

JP Morgan Chase’s Cognition Therapeutics CGTX Stock Holding History

JP Morgan Chase’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-69
Closed -$29 – 7136
2025
Q1 		$29 Sell
69
-6
-8% -$4 ﹤0.01% 7073
2024
Q4 		$53 Sell
75
-3
-4% -$1 ﹤0.01% 7118
2024
Q3 		$37 Buy
+78
New +$80 ﹤0.01% 7163
2024
Q2 		– Sell
-70
Closed -$127 – 7387
2024
Q1 		$127 Buy
70
+35
+100% +$72 ﹤0.01% 6871
2023
Q4 		$65 Buy
35
+10
+40% +$13 ﹤0.01% 7170
2023
Q3 		$36 Sell
25
-25
-50% -$39 ﹤0.01% 7047
2023
Q2 		$92 Buy
+50
New +$106 ﹤0.01% 6702

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return

JP Morgan Chase's CGTX Position: Q2 2025 in Review

JP Morgan Chase sold out of Cognition Therapeutics (CGTX) in Q2 2025, closing a stake of 69 shares — an estimated $29 sold.

JP Morgan Chase first reported a position in CGTX in Q2 2023 and held it in 7 quarters. The position peaked at $127 in Q1 2024. 48 funds tracked by Wall St. Rank hold CGTX as of Q2 2025.

  • JP Morgan Chase reported no remaining Cognition Therapeutics position as of Q2 2025 after selling out during the quarter.
  • JP Morgan Chase sold 69 Cognition Therapeutics shares in Q2 2025, an estimated $29.
  • JP Morgan Chase first reported a position in Cognition Therapeutics in Q2 2023 and held it in 7 quarters.
  • JP Morgan Chase's Cognition Therapeutics position peaked at $127 in Q1 2024.
  • 48 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q2 2025.

Based on JP Morgan Chase's 13F filing for Q2 2025, filed 12 Aug 2025.